Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000737

Drug Information
NameCelecoxib
SynonymsKBioGR_000723; NCGC00091455-01; SMR000550473; Celebrex (TN); CHEMBL118; Onsenal; KBio2_002351; LS-31667; Celecoxib [Old RN]; KBio2_000912; CPD000550473; CHEBI:41423; CID2662; AI-525; MLS001195656; Solexa; C07589; KBio3_003037; benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-; Celebra; SC-58635; YM177; Medicoxib; S1261_Selleck; Celecoxib (SC-58635); HMS502M15; Celecoxi; 184007-95-2; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; SC 58635; SAM002589995; Spectrum5_001324; Celecox; Spectrum_000432; HSDB 7038; Spectrum4_000182; YM 177; KBio3_002830; KBioSS_000912; KBio1_000893; 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; FT-0080064; BSPBio_003596; AC1L1E6K; Celecoxib [USAN]; NINDS_000893; Benzenesulfonamide, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-; DB00482; Celocoxib; SPBio_001512; SC58635; KBio2_004919; HMS2089L18; ZINC02570895; Spectrum2_001576; cMAP_000027; BRD-K02637541-001-02-4; KBio2_003480; Xilebao; NCGC00091455-04; AC-4228; CCRIS 8679; UNM-0000305813; Pfizer brand of celecoxib; NCI60_041049; KBio2_006048; D00567; I01-1033; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide; NCGC00091455-03; TL8001323; DivK1c_000893; Spectrum3_001996; C17H14F3N3O2S; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; KBioGR_002351; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 169590-42-5; Celebrex; YM-177; BIDD:GT0408; NSC719627; CEL; MLS001304708; TPI-336; KBioSS_002354; 1oq5; Celecoxib (JAN/USAN/INN); Celebrex, Celebra, Celecoxib; SC-58553, SC-58635; Eurocox; IDI1_000893; p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; HMS2093I07; C105934; SPECTRUM1503678; KBio2_007487; MolPort-002-885-815; MLS001165684; NCGC00091455-02; celecoxib; CEP-33222; HMS1922G14
Trade NameCelebrex; Celebra
CompanyPfizer
IndicationPain
[ICD9: 338,780   ICD10: R52, G89]
Phase III    [1]
Rheumatoid arthritis and osteoarthritis
[ICD9: 714, 715   ICD10: M05-M06, M15-M19, M47]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(1
5)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
InChIKeyRZEKVGVHFLEQIL-UHFFFAOYSA-N
Canonical SMILESCC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F    
Therapeutic ClassAnalgesics
CAS NumberCAS 169590-42-5
FormulaC17H14F3N3O2S
PubChem Compound IDCID 2662.
PubChem Substance IDSID 9791.
ChEBI41423;
SuperDrug ATC IDL01XX33; M01AH01
SuperDrug CAS ID169590425;
TargetCyclooxygenase-2Inhibitor[2][3][4]
Cyclooxygenase-2Inhibitor[5][4][6][7][8][7][9][10]
Ref 1New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. To Reference
Ref 2Pfizer. Product Development Pipeline. March 31 2009. To Reference
Ref 3Pfizer. News for Pfizer. March 31 2009. To Reference
Ref 4Mini Rev Med Chem. 2007 Nov;7(11):1108-19.Privileged structures: a useful concept for the rational design of new lead drug candidates. To Reference
Ref 5Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-Independent Manner. J Cell Biochem. 2009 Jun 26. [Epub ahead of print] To Reference
Ref 6A randomized, clinical trial comparing oral celecoxib 200 mg, celecoxib 400 mg, and ibuprofen 600 mg for acute pain. Acad Emerg Med. 2003 Jan;10(1):22-30. To Reference
Ref 7Valdecoxib (Pharmacia). Curr Opin Investig Drugs. 2002 Feb;3(2):240-5. To Reference
Ref 8Clinical experience with cyclooxygenase-2 inhibitors. Rheumatology (Oxford). 2002 Apr;41 Supp 1:16-22; discussion 35-42. To Reference
Ref 9New and future drug therapies for rheumatoid arthritis. Rheumatology (Oxford). 2000 Jun;39 Suppl 1:36-42. To Reference
Ref 10The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 2000 Sep 15;60(18):5040-4. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543